232 related articles for article (PubMed ID: 35163539)
1. Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches.
Sadiea RZ; Sultana S; Chaki BM; Islam T; Dash S; Akter S; Islam MS; Kazi T; Nagata A; Spagnuolo R; Mancina RM; Hossain MG
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163539
[TBL] [Abstract][Full Text] [Related]
2. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH
J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
[TBL] [Abstract][Full Text] [Related]
3. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication.
Hu Z; Hu J; Ren F; Xu H; Tan M; Wang Q; Ren J
Biochem Biophys Res Commun; 2020 Mar; 523(3):802-808. PubMed ID: 31954513
[TBL] [Abstract][Full Text] [Related]
4. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity.
Hu Y; Cheng X; Cao F; Huang A; Tavis JE
Antiviral Res; 2013 Sep; 99(3):221-9. PubMed ID: 23796982
[TBL] [Abstract][Full Text] [Related]
5. Drug targets in hepatitis B virus infection.
Stein LL; Loomba R
Infect Disord Drug Targets; 2009 Apr; 9(2):105-16. PubMed ID: 19275699
[TBL] [Abstract][Full Text] [Related]
6. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
7. [Research progress on the effect of hepatitis B virus DNA integration on antiviral therapy].
Zhao J; Chen XY; Zheng SJ
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):375-379. PubMed ID: 38733195
[TBL] [Abstract][Full Text] [Related]
8. Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes.
Cui XJ; Cho YK; Song BC
J Med Virol; 2015 Apr; 87(4):601-8. PubMed ID: 25612255
[TBL] [Abstract][Full Text] [Related]
9. Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs.
Wu C; Li B; Zhang X; Zhao K; Chen Y; Yuan Y; Liu Y; Chen R; Xu D; Chen X; Lu M
Virol Sin; 2019 Aug; 34(4):377-385. PubMed ID: 31218588
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside analogs as anti-HBV agents.
Zhou XX; Littler E
Curr Top Med Chem; 2006; 6(9):851-65. PubMed ID: 16787280
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity.
Cai CW; Lomonosova E; Moran EA; Cheng X; Patel KB; Bailly F; Cotelle P; Meyers MJ; Tavis JE
Antiviral Res; 2014 Aug; 108():48-55. PubMed ID: 24858512
[TBL] [Abstract][Full Text] [Related]
13. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
14. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance--implications for novel antiviral strategies.
Tacke F; Manns MP; Trautwein C
Curr Med Chem; 2004 Oct; 11(20):2667-77. PubMed ID: 15544468
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.
Zhou YB; Wang YF; Zhang Y; Zheng LY; Yang XA; Wang N; Jiang JH; Ma F; Yin DT; Sun CY; Wang QD
Eur J Pharmacol; 2012 May; 683(1-3):10-5. PubMed ID: 22387093
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel anti-hepatitis B virus agent via Sp1.
Hayakawa M; Umeyama H; Iwadate M; Taguchi YH; Yano Y; Honda T; Itami-Matsumoto S; Kozuka R; Enomoto M; Tamori A; Kawada N; Murakami Y
Sci Rep; 2020 Jan; 10(1):47. PubMed ID: 31913341
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
18. [From the Establishment of Hepatitis B Virus Cell Culture Systems to Drug Discovery].
Fukano K; Watashi K
Yakugaku Zasshi; 2019; 139(1):81-87. PubMed ID: 30606935
[TBL] [Abstract][Full Text] [Related]
19. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.
Kubo S; Takemura S; Tanaka S; Shinkawa H; Nishioka T; Nozawa A; Kinoshita M; Hamano G; Ito T; Urata Y
World J Gastroenterol; 2015 Jul; 21(27):8249-55. PubMed ID: 26217076
[TBL] [Abstract][Full Text] [Related]
20. A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.
Luo YY; Tao Y; Cai XF; Zhang WL; Long QX; Guo H; Huang AL; Hu JL
Antiviral Res; 2016 Feb; 126():99-107. PubMed ID: 26738784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
